• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    11/27/23 4:31:02 PM ET
    $ACRX
    $CNTA
    $COCH
    $HSCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • SenesTech (NASDAQ:SNES) stock rose 42.0% to $2.67 during Monday's after-market session.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 17.71% to $0.49. The market value of their outstanding shares is at $4.6 million.
    • Heart Test Laboratories (NASDAQ:HSCS) stock rose 15.99% to $0.25. The company's market cap stands at $12.0 million.
    • UpHealth (NYSE:UPH) shares rose 10.66% to $0.54. The company's market cap stands at $9.2 million.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) shares moved upwards by 8.1% to $0.8. The market value of their outstanding shares is at $13.5 million.
    • Sientra (NASDAQ:SIEN) stock rose 7.23% to $0.83. The company's market cap stands at $9.9 million.

    Losers

    • Centessa Pharmaceuticals (NASDAQ:CNTA) stock fell 10.6% to $5.81 during Monday's after-market session. The market value of their outstanding shares is at $567.2 million.
    • Redhill Biopharma (NASDAQ:RDHL) stock fell 6.89% to $0.93. The company's market cap stands at $10.3 million.
    • OneMedNet (NASDAQ:ONMD) shares decreased by 6.07% to $3.56. The company's market cap stands at $114.8 million.
    • Tharimmune (NASDAQ:THAR) stock fell 5.7% to $3.31. The market value of their outstanding shares is at $2.3 million.
    • Envoy Medical (NASDAQ:COCH) shares fell 5.04% to $1.32. The market value of their outstanding shares is at $25.8 million.
    • Leap Therapeutics (NASDAQ:LPTX) stock decreased by 5.0% to $2.47. The company's market cap stands at $63.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $CNTA
    $COCH
    $HSCS

    CompanyDatePrice TargetRatingAnalyst
    Centessa Pharmaceuticals plc
    $CNTA
    2/24/2026$40.00Outperform
    Wolfe Research
    Centessa Pharmaceuticals plc
    $CNTA
    12/10/2025$62.00Outperform
    Oppenheimer
    Centessa Pharmaceuticals plc
    $CNTA
    10/28/2025$35.00Overweight
    Stephens
    Centessa Pharmaceuticals plc
    $CNTA
    9/3/2025$31.00Overweight
    Wells Fargo
    Centessa Pharmaceuticals plc
    $CNTA
    8/29/2025$40.00Outperform
    Oppenheimer
    Centessa Pharmaceuticals plc
    $CNTA
    7/21/2025$30.00Buy
    Truist
    Centessa Pharmaceuticals plc
    $CNTA
    5/28/2025$35.00Buy
    Needham
    Centessa Pharmaceuticals plc
    $CNTA
    5/8/2025$30.00Buy
    Chardan Capital Markets
    More analyst ratings

    $ACRX
    $CNTA
    $COCH
    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

    Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category. MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making. The platform supports integration with hospital information systems and electronic health records ("EHRs"), including

    3/25/26 8:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings

    Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET. Hosted by Investor Summit Group, a premier platform connecting microcap companies with leading investors, the event provides a highly efficient forum for emerging growth companies to engage directly with institutional investors, family offices, and high-net-worth individuals. Event Details: Conference: Inves

    3/24/26 11:18:08 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    Envoy Medical Reports Full Year 2025 Financial Results

    Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to final stageStrengthened balance sheet by extinguishing $32 million in debtSubsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind fully implanted cochlear implantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 23, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced its corporate and financial results for the full year ended December 31, 2025, as

    3/23/26 8:30:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $ACRX
    $CNTA
    $COCH
    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Anderson Karen M.

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    3/27/26 6:17:05 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Weinhoff Gregory M

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    3/26/26 8:36:04 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Tsimchi Ofer

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/19/26 7:35:14 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $CNTA
    $COCH
    $HSCS
    SEC Filings

    View All

    Envoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    3/27/26 4:01:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 144 filed by Centessa Pharmaceuticals plc

    144 - Centessa Pharmaceuticals plc (0001847903) (Subject)

    3/26/26 4:22:20 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Centessa Pharmaceuticals plc

    144 - Centessa Pharmaceuticals plc (0001847903) (Subject)

    3/26/26 4:05:45 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $CNTA
    $COCH
    $HSCS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ACRX
    $CNTA
    $COCH
    $HSCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Centessa Pharmaceuticals with a new price target

    Wolfe Research initiated coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:47:48 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Centessa Pharmaceuticals with a new price target

    Oppenheimer resumed coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $62.00

    12/10/25 8:21:56 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Centessa Pharmaceuticals with a new price target

    Stephens initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $35.00

    10/28/25 8:03:12 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $CNTA
    $COCH
    $HSCS
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ACRX
    $CNTA
    $COCH
    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

    SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    11/14/24 5:43:48 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $CNTA
    $COCH
    $HSCS
    Financials

    Live finance-specific insights

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care